Alphatec beats Q2 revenue estimates, raises FY guidance
Overview
Alphatec Q2 revenue grows 27.5%, beating analysts' expectations, per LSEG data
Adjusted EBITDA for Q2 beats consensus, reflecting disciplined execution
Company raises full-year revenue and profitability guidance
Outlook
Company expects full-year 2025 revenue to grow 21% to $742 mln
Alphatec raises full-year 2025 adjusted EBITDA guidance to $83 mln
Company projects 2025 surgical revenue of $666 mln
Alphatec anticipates EOS revenue of $76 mln in 2025
Result Drivers
SURGICAL REVENUE - 29% growth driven by momentum of PTP™ and LTP™ solutions
SURGEON ADOPTION - 21% increase in new surgeon adoption, indicating future growth potential
EBITDA MARGIN EXPANSION - Adjusted EBITDA margin expanded by 880 bps YoY through disciplined execution
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $186 mln | $178.80 mln (9 Analysts) |
Q2 Net Income | -$41 mln | ||
Q2 Adjusted EBITDA | Beat | $23 mln | $17.80 mln (8 Analysts) |
Q2 Gross Margin | 70.0% | ||
Q2 Adjusted Gross Margin | 70.0% | ||
Q2 Basic EPS | -$0.27 | ||
Q2 Operating Income | -$13.08 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Alphatec Holdings Inc is $20.00, about 46.3% above its July 30 closing price of $10.73
Press Release:
